argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16 2023 - 01:30PM
GlobeNewswire Inc.
January 16,
2023
Amsterdam, the
Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
an extraordinary general meeting of shareholders will be held at
12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam
Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the
Netherlands.The shareholders and all other persons with meeting
rights are invited to attend the extraordinary general meeting of
shareholders. The formal notice of convocation (including
information on attending the meeting in person or by proxy,
requirements for notification and registration for the meeting and
regarding the e-voting system) is available on the argenx website
www.argenx.com and on www.abnamro.com/evoting.
AgendaThe sole voting item on
the agenda will be the proposed appointment of Mr. Steve Krognes as
non-executive director and Chair of the Audit and Compliance
Committee of the Company’s Board of Directors.
The full agenda for the meeting, as well as all
ancillary documents relevant for the meeting are available via the
argenx website and are also available for inspection at the argenx
offices. A free copy thereof may also be obtained by e-mailing
legal@argenx.com. argenx would like to encourage shareholders to
use the voting by (electronic) proxy option as referred to in the
convocation.
Resignation Werner
LanthalerUpon appointment of Mr. Krognes, Werner Lanthaler
will resign as non-executive director of the Board and Chair of the
Audit and Compliance Committee to enable this important step in the
long term succession planning for the board of directors and the
audit and compliance committee chairperson role. The Company would
like to express its gratitude towards Werner Lanthaler for his
substantial contributions over the last eight years. Werner's
entrepreneurial nature combined with broad experience in finance,
executive leadership, and life sciences has helped guide argenx
from a research-focused company to a fully integrated
commercial-stage global immunology company.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and-only approved
neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU.
The Company is evaluating efgartigimod in multiple serious
autoimmune diseases and advancing several earlier stage
experimental medicines within its therapeutic franchises. For more
information, visit www.argenx.com and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:Kelsey
Kirkkkirk@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Argen X (EU:ARGX)
Historical Stock Chart
From May 2023 to Jun 2023
Argen X (EU:ARGX)
Historical Stock Chart
From Jun 2022 to Jun 2023
